Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neill J Liptrott

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Drug Delivery and Translational Research|July 15, 2022
An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplarsRob J Vandebriel, Christopher A W David, Jolanda P Vermeulen, et al.
Nanomedicine (London, England)|August 15, 2017
Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune systemNeill J Liptrott, Marco Giardiello, Tom O McDonald, et al.
Pharmacology Research & Perspectives|October 4, 2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation ratesChristina Chan, Philip Martin, Neill J Liptrott, et al.
Journal of Nanobiotechnology|March 17, 2018
Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systemsNeill J Liptrott, Marco Giardiello, Tom O McDonald, et al.
Nanotoxicology|January 6, 2017
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicinesMatthias Rösslein, Neill J Liptrott, Andrew Owen, et al.
International Journal of Molecular Sciences|May 25, 2024
Nano(bio)Materials Do Not Affect Macrophage Phenotype-A Study Conducted by the REFINE ProjectChristopher A W David, Jolanda P Vermeulen, Sabrina Gioria, et al.
Antimicrobial Agents and Chemotherapy|September 5, 2013
Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroDarren M Moss, Neill J Liptrott, Paul Curley, et al.
International Journal of Molecular Sciences|August 9, 2020
In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear CellsChristopher A W David, Michael Barrow, Patricia Murray, et al.
Therapeutic Delivery|January 25, 2013
Nanomedicines for HIV therapyMarco Siccardi, Philip Martin, Tom O McDonald, et al.
Nanomedicine (London, England)|June 19, 2014
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'Neill J Liptrott, Emily Kendall, Daniel J Nieves, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Drug Delivery and Translational Research|July 15, 2022
An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplarsRob J Vandebriel, Christopher A W David, Jolanda P Vermeulen, et al.
Nanomedicine (London, England)|August 15, 2017
Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune systemNeill J Liptrott, Marco Giardiello, Tom O McDonald, et al.
Pharmacology Research & Perspectives|October 4, 2017
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation ratesChristina Chan, Philip Martin, Neill J Liptrott, et al.
Journal of Nanobiotechnology|March 17, 2018
Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systemsNeill J Liptrott, Marco Giardiello, Tom O McDonald, et al.
Nanotoxicology|January 6, 2017
Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicinesMatthias Rösslein, Neill J Liptrott, Andrew Owen, et al.
International Journal of Molecular Sciences|May 25, 2024
Nano(bio)Materials Do Not Affect Macrophage Phenotype-A Study Conducted by the REFINE ProjectChristopher A W David, Jolanda P Vermeulen, Sabrina Gioria, et al.
Antimicrobial Agents and Chemotherapy|September 5, 2013
Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroDarren M Moss, Neill J Liptrott, Paul Curley, et al.
International Journal of Molecular Sciences|August 9, 2020
In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear CellsChristopher A W David, Michael Barrow, Patricia Murray, et al.
Therapeutic Delivery|January 25, 2013
Nanomedicines for HIV therapyMarco Siccardi, Philip Martin, Tom O McDonald, et al.
Nanomedicine (London, England)|June 19, 2014
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'Neill J Liptrott, Emily Kendall, Daniel J Nieves, et al.
Pageof 5